Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 8/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841901 | 1.00 | SMYD3 (0.37) | SMYD3CCR5SIGMAR1SLC18A3OPRM1 | |
| SCHEMBL4845113 | 0.88 | CCR5 (0.36) | SMYD3CCR5SIGMAR1SLC18A3PSEN1 | |
| SCHEMBL4841364 | 0.88 | CCR5 (0.36) | SMYD3CCR5SIGMAR1SLC18A3PSEN1 | |
| SCHEMBL4842758 | 0.86 | SIGMAR1 (0.36) | SMYD3CCR5SIGMAR1SLC18A3OPRM1 | |
| SCHEMBL4841604 | 0.86 | SIGMAR1 (0.36) | SMYD3CCR5SIGMAR1SLC18A3OPRM1 | |
| SCHEMBL4843278 | 0.86 | SIGMAR1 (0.36) | SMYD3CCR5SIGMAR1SLC18A3OPRM1 | |
| SCHEMBL4842145 | 0.85 | KCNH2 (0.35) | CCR5OPRM1DRD2PSEN1PSEN2 | |
| SCHEMBL4842388 | 0.85 | KCNH2 (0.35) | CCR5OPRM1DRD2PSEN1PSEN2 | |
| SCHEMBL4842196 | 0.85 | KCNH2 (0.35) | CCR5OPRM1DRD2PSEN1PSEN2 | |
| SCHEMBL4843465 | 0.85 | KCNH2 (0.35) | CCR5OPRM1DRD2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | claimed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | claimed |
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183732-A1 | Novel lactams and uses thereof | BACE1, BACE2, APP | SMYD3 4425/4885CCR5 4144/4885SIGMAR1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.